Nuvation Bio Inc.

NYSE:NUVB

Biotechnology

Healthcare
$3.78 +1.03%

+$0.06 today

Market cap
$1.33B
Beta
1.56
P/E (TTM)
-12.8
EPS (TTM)
-$0.42
52W Low $1.81High $9.75

Volume 5.96M

Average 4.07M

NUVB Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Nuvation Bio Inc.NYSE: NUVB

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development grows, but more slowly than its trailing trend

Q2 FY2026 research & development of $30.66M rose 12.1% year over year, behind the +18.2% change in trailing-twelve-month research & development. Sequentially, it fell 12.5% from the prior quarter. Over 3 fiscal years it compounded at +9.4% a year.

Context

  • Research & development amounted to 183.0% of revenue in FY2025, down 6475.1 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +12.1% toward the trailing-twelve-month pace of +18.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$30.66M-12.5% QoQ
Last fiscal yearDec 2025
$115.11M-78.0% YoY
LTMJun 2026
$128.85M+18.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.1%——
1 year-78.0%——
3-year CAGR+9.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
115.11M USD
Year-over-year change
-78.0%
4-year CAGR
+13.6%

Research & Development vs competitors

How NUVB compares with its peers on the latest reported figures

  • NUVB's LTM Jun 2026 research & development of $128.85M is the 9th highest of the 11 companies compared; the peer median is $203.36M.
  • Its year-over-year change of +18.2% is the 7th highest of 11, against a peer median of +39.2%.
  • Research & development amounts to 75.8% of revenue for NUVB, versus a peer median of 456.5%.
NUVB Competitors Peer median
Research & Development for NUVB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VRDNViridian Therapeutics, Inc.LTM Jun 2026$324.68M +6.6%+49.8%456.5%
GPCRStructure Therapeutics Inc.LTM Jun 2026$294.44M +79.9%+83.9%—
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$283.32M +31.2%+43.9%252960.7%
VERAVera Therapeutics, Inc.LTM Jun 2026$261.87M +51.3%+45.5%—
OCULOcular Therapeutix, Inc.LTM Mar 2026$220.45M +47.2%+54.5%423.6%
ABCLAbCellera Biologics Inc.LTM Sep 2026$186.28M +1.9%+20.1%274.5%
EWTXEdgewise Therapeutics, Inc.LTM Sep 2026$165.37M +14.7%+41.0%—
QUREuniQure N.V.LTM Mar 2026$132.76M -4.7%-10.7%733.7%
NUVBNuvation Bio Inc.LTM Jun 2026$128.85M +18.2%+9.4%75.8%
JANXJanux Therapeutics, Inc.LTM Mar 2026$127.65M +60.8%+33.1%590.6%
AUPHAurinia Pharmaceuticals Inc.LTM Jun 2026$39.85M +63.8%-10.3%12.8%
Peer median (excluding NUVB) $203.36M+39.2%+42.4%456.5%

Competitors are the stored peer set for NUVB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0007.87M62.9M
Cost of Revenue0007.08M8.44M
Gross Profit000795K54.46M
Gross Margin———10.1%86.6%
Research & Development69.04M87.82M71.29M524.19M115.11M
Selling, General & Admin24.28M31.92M28.53M69.23M151.56M
Operating Expenses93.32M119.73M99.82M593.42M267.52M
Depreciation & Amortization184K199K222K683K1.74M
EBITDA(86.66M)(104M)(75.58M)(566.92M)(189.21M)
EBITDA Margin———-7200.7%-300.8%
Operating Income(93.32M)(119.73M)(99.82M)(592.63M)(213.06M)
Operating Margin———-7527.3%-338.7%
Interest Income2.96M7.45M24.61M27.06M21.43M
Interest Expense000341K13.68M
Other Income / Expenses6.47M15.54M24.02M24.69M8.44M
Income Before Tax(86.85M)(104.2M)(75.8M)(567.94M)(204.63M)
Pre-Tax Margin———-7213.8%-325.3%
Income Tax Expense00000
Net Income(86.85M)(104.2M)(75.8M)(567.94M)(204.63M)
Net Margin———-7213.8%-325.3%
EPS (Basic)(0.44)(0.48)(0.35)(2.11)(0.60)
EPS (Diluted)(0.44)(0.48)(0.35)(2.11)(0.60)
Weighted Avg Shares197.89M216.72M218.88M268.77M341.54M
Weighted Avg Shares (Diluted)197.89M216.72M218.88M268.77M341.54M

Nuvation Bio Inc.

NYSE:NUVB

Intrinsic Alpha fair value

Locked

Current Price

$3.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.